Tobacco and alcohol consumption are the most well known risk factors for the development of oropharyngeal squamous cell carcinomas (OPC; [@bib12]). However, Human Papillomavirus (HPV) infection, particularly type 16, is now recognised as a major aetiological factor of carcinogenesis in these cancers ([@bib25]; [@bib38]). The detection of an active HPV infection is variably appreciated in the literature. It is now admitted that the presence of both HPV DNA and mRNA encoding HPV oncogenic proteins E6/7 in tumours clearly identifies a clinically active infection involved in carcinogenesis ([@bib20]; [@bib15]). HPV-related OPC are frequently associated with lymph node metastases ([@bib37]; [@bib19]). However, they respond better to treatments (surgery, radiotherapy and chemotherapy) than tumours associated with traditional risk factors ([@bib34]; [@bib7]) and generally they have a significantly favourable survival outcome. At the present time, the number of these tumours is dramatically increasing, reaching up to 72% in some countries, which led some authors to use the term of a growing epidemic ([@bib11]; [@bib2]; [@bib16]; [@bib30]; [@bib5]).

Epithelial to mesenchymal transition (EMT) is characterised by diminished epithelial characteristics such as a reorganisation of intercellular junctions, including E-cadherin and *β*-catenin expression, and enhanced mesenchymal attributes such as increased expression of vimentin, fibronectin and proteolytic enzymes. EMT has been described in embryologic morphogenesis, fibrosis and lately in tumour invasion and metastasis processes ([@bib39]; [@bib22]). In carcinomas, EMT is also associated to cancer stem cell properties ([@bib29]). EMT has been reported in head and neck squamous cell carcinomas (HNSSC) and generally associated with a poor prognosis ([@bib1]; [@bib46]; [@bib24]; [@bib17]; [@bib31]; [@bib45]; [@bib26]; [@bib44]; [@bib13]; [@bib33]; [@bib4]; [@bib18]; [@bib36]; [@bib41]). Moreover, EMT predicts drug resistance in HNSSC cell lines ([@bib8]). However, the literature investigating the expression of EMT markers and their correlation with HPV status and prognosis is poor in OPC with limited series of patients ([@bib31]; [@bib13]; [@bib41]).

Thus, the aim of the present work is to study the relationship of EMT markers, with HPV infection (DNA and RNA) and survival outcome in a large cohort of 296 OPC in well clinically characterised patients, to get new insights in the prognosis of OPC.

Materials and Methods
=====================

Patients and tumours
--------------------

The PAPILLOPHAR study is a prospective cohort of 340 adult patients with OPC recruited from May 2009 to April 2012 in 14 French centres. Patients were followed according to the recommendations of the French Otolaryngology, Head and Neck Surgery Society: every 2 months during the first year and every 3 months during the second year. All patients provided written informed consent. The study was approved by the ethical committee (Comité de Protection des Personnes Ile-de-France III), and French data protection authority (Commission Nationale de l\'Informatique et des Libertés). Clinical Trials.gov was NCT00918710.

HPV status
----------

High risk HPV DNA and E6/E7 mRNA were detected from frozen biopsies using the INNO-LIPA kit (Innogenetics, Gent, Belgium) and the NucliSENS EasyQ kit (bioMérieux, Marcy-l\'Etoile, France), respectively. E6/E7 mRNA detection was performed in DNA positive tumours. Positive HPV status was defined as both positive DNA and E6/E7 mRNA detection.

Immunohistochemistry
--------------------

Serial tissue sections of 4-*μ*m-thick were performed on formalin-fixed paraffin-embedded blocks of OPC, at initial diagnosis. Immunohistochemistry was performed with antibodies against cytokeratins (Dako Glostrup, Denmark, Ref H3515, dilution 1: 50, clone AE1/AE3), E-cadherin (Dako Ref M3612 dilution: 1: 50, clone NCH-38), *β*-catenin (Cell marque Ref 7604242 pre-diluted ready to use, clone 14), vimentin (Dako, Ref MO725, dilution 1 : 600, clone V9) for EMT and antibody against p16^INK4a^ (Ventana Cintec p16 Histology Ref 805--4713, pre-diluted ready to use, clone E6H4), classically considered as a marker of an active HPV infection in the literature. Subsequent steps were performed with the ultraView universal DAB detection kit (Ventana). Ventana Benchmark XT autostainer (Ventana Medical Systems, Inc., Tucson, AZ, USA) was used for all these immunohistochemical studies.

Histological evaluation of the tumours and scoring of the results for immunohistochemical detection of keratins, vimentin, E-cadherin and *β*-catenin were centralised and assessed by two pathologists who had no knowledge of the clinical data. When a discrepancy was found between the two investigators, a consensus was reached via simultaneous examination using a double-headed microscope.

Tumour differentiation was evaluated according to the detection of intercellular bridges and keratinisation with variable 'pearl\' formation, and graded into well-, moderately and poorly differentiated squamous cell carcinomas according to the Classification of Head and Neck tumours of the World Health Organization.

EMT is defined by a loss of epithelial markers such as cytokeratins and cell adhesion molecules and vimentin expression. Scoring for immunohistochemistry of cytokeratins, E-cadherin and *β*-catenin was as follows: 0=no detection, 1=detection in \<10% of tumour cells, 2=detection in 10--25% of tumour cells, 3=detection in 25--50% of tumour cells, 4=detection in \>50% of tumour cells. Cytokeratins were detected in the cytoplasm of tumour cells and we took into account cell membrane staining of epithelial cell adhesion molecules, E-cadherin and *β*-catenin, for the evaluation of their immunohistochemical detection. Nuclear detection of *β*-catenin, a good marker of EMT as a co-transcription factor of genes implicated in this process ([@bib27]), was also specified in the results. In addition, for E-cadherin and *β*-catenin, the intensity of staining was graded as follows: 1 for background staining, 2 for weak staining, 3 for moderate staining and 4 for strong staining. Subsequently, for these two markers, both scores were multiplied resulting in the final expression score ranging from 0 to 16.

Vimentin expression is associated with changes in cell shape, motility and adhesion during EMT ([@bib32]) and has been largely used in the literature to identify tumour cells undergoing EMT with a fibroblastoid phenotype in carcinomas ([@bib9]; [@bib23], [@bib43] and particularly in OPC ([@bib13]; [@bib36]; [@bib41]). The percentage of vimentin expression by cancer cells within the tumour is a relevant prognostic marker ([@bib6]; [@bib13]; [@bib41]). Thus, EMT was graded according to cytoplasmic vimentin expression scoring as follows: 0=no EMT for vimentin score from 0 to 10%, 1=mild EMT for vimentin score between 11 and 25%, 2=overt EMT for vimentin score above 25%.

p16^INK4a^ was considered as positive when \>80% tumour cells were stained with a strong cytoplasmic and nuclear labelling.

Study endpoints
---------------

Metastasis-free survival (MFS) was defined as the time from the date of OPC diagnosis to the date of distant metastases. Progression-free survival (PFS) was defined as the time from the date of OPC diagnosis to the date of first documented relapse, categorised as loco-regional disease (tumour at the primary site or regional nodes) or the date of distant metastasis or the date of cancer-related death. Overall survival (OS) was calculated as the time from the date of OPC diagnosis to the date of cancer-related death.

Statistical analysis
--------------------

In agreement with epidemiological data, tobacco smoking was classified according to current status and duration of cessation among former users into three groups: (1) never-smokers (\<100 cigarettes in lifetime); (2) long-duration former smokers (⩾10 year-cessation); and (3) current smokers or recent former smokers (\<10 year-cessation). Pack-years (P/Y) were also estimated for current and former smokers for \<10 years and classified as below or above the median (40 P/Y). Alcohol consumption was classified into: (1) never- and occasional drinkers (\<1 drink per day) and long-duration former drinkers (⩾10 year-cessation); and (2) current and short-term (\<10 years) drinkers. The large number of treatment combinations used in Papillophar was classified according to initial treatment into: (1) up-front surgery; (2) up-front radiotherapy; (3) induction chemotherapy. Owing to the limited numbers of the (0--8) E-cadherin expression level, (0--8) and (8--12) levels have been gathered for prognosis analysis.

Qualitative variables were expressed as percentage and effective and compared using *χ*^2^ test or Fisher exact test when appropriate. Continuous variables were expressed as mean and s.d. Missing values were not replaced.

Follow-up was truncated at 30 months. Survival curves were estimated using Kaplan--Meier method (Greenwood variance). Prognostic value of EMT markers was evaluated in univariate analysis using Cox proportional hazard model. Multivariate analyses were performed when *P*-value was ⩽0.20 in univariate analysis. Multivariate analyses were adjusted, as appropriate, for all variables shown in univariate analyses, including HPV status. HR and corresponding 95% confidence intervals (CIs) were computed. *P*-value\<0.05 was considered to achieve statistical significance. Analyses were performed using SAS V.9.3 software (SAS Institute, Cary, NC, USA).

Results
=======

Among the 340 patients included in the PAPILLOPHAR study, 296 patients with OPC have been investigated for EMT markers. Baseline characteristics of the patients are shown in [Table 1](#tbl1){ref-type="table"}.

Out of 296 patients, 77 (26.01%) were HPV DNA and HPV E6/E7 mRNA positive. Out of them, 28 (36.36%) were current smokers or recent former smokers (\<10 year-cessation).

Multivariate analyses (without taking in account EMT markers) confirmed that HPV status is an independent prognostic factor for PFS (HR=0.41 (0.23; 0.74)), OS (HR=0.19 (0.09; 0.43)), but not for MFS (*P*=0.15, data not shown).

Histology and immunohistochemical findings
------------------------------------------

([Table 1](#tbl1){ref-type="table"}) Diagnosis of basaloid tumour was more frequent in HPV positive than in HPV negative tumours (15,6% *vs* 5,5%, *P*= 0.0052) and lack of differentiation of the OPC was more frequent in HPV positive than in HPV negative tumours (75.3% *vs* 40.6%, *P*\<0.0001). Cytokeratins were consistently present in tumour cells. E-cadherin and *β*-catenin were largely expressed at the tumour cell membranes ([Figures 1C and D](#fig1){ref-type="fig"}), with scores of 12--16 in 90.5% of cases for E-cadherin and scores of 12--16 in 85.5% for *β*-catenin. Nuclear *β*-catenin was detected in 3.7% of OPC, all these cases expressing vimentin in \>25% of tumour cells. Neither E-cadherin nor *β*-catenin expressions were related to HPV status (data not shown). Vimentin expression was observed in tumour cells, principally at invasion fronts of the tumour clusters and individual invasive cells ([Figure 1B](#fig1){ref-type="fig"}). Vimentin was frequently co-expressed in E-cadherin positive cells, but was consistently detected in E-cadherin negative tumour cells. Vimentin was detected in 175 tumours including 81 (27.4%)⩽10% of positive cells, 34 (11.5%) between 10 and 25%, 23 (7.8%) between 25 and 50% and 37 (12.5%) more than 50% of positive cells. Considering vimentin expression, EMT was not significantly related to HPV status (no EMT =64.8%, mild EMT =12.8%, overt EMT=22.4% in HPV negative tumours *vs* 77.9, 7.8 and 14.3% in HPV-positive tumours, respectively, *P*=0.1139).

EMT was not related to basaloid tumours (*P*=0.2086) and overt EMT was more frequent among poorly differentiated tumour than in moderately or well differentiated tumour (27.2, 15.2 and 9.1, respectively, *P*=0.0491).

p16^INK4a^ was considered as positive in one third of OPC ([Figure 1A](#fig1){ref-type="fig"}). There was an association between p16^INK4a^ detection and EMT: overt EMT was less frequent in p16^INK4a^ positive tumours than in negative tumours (p16^INK4a^ negative: no EMT =62.56%, mild EMT =13.85%, overt EMT=23.59% *vs* p16^INK4a^ positive: no EMT 79.21%, mild EMT 6.93%, overt EMT =13.86%, *P*=0.0137). However, it has to be emphasised that 24 tumours positive for p16^INK4a^ were HPV negative.

Prognostic value of *β*-catenin and E-cadherin
----------------------------------------------

In univariate analysis, *β*-catenin and nuclear *β*-catenin were not related to the survival outcomes. Lower level of E-cadherin expression was associated with higher risk of distant metastasis in univariate analysis (*P*=0.0110, [Figure 2C](#fig2){ref-type="fig"}), and this was confirmed in multivariate analysis (HR=6.86 (1.98; 23.84), [Table 2](#tbl2){ref-type="table"}). E-cadherin expression was not related with the other endpoints.

Prognostic value of EMT considering vimentin expression
-------------------------------------------------------

In univariate analysis, overt EMT was associated with higher risk of distant metastasis (*P*=0.0173). As mild EMT showed similar risk of metastasis than the absence of EMT (HR=2.16 (0.59; 7.93)), the two levels were pooled for further analysis. Univariate and multivariate analysis are shown in [Table 2](#tbl2){ref-type="table"} and survival curves in [Figure 2A](#fig2){ref-type="fig"}. In multivariate analysis, higher risk of metastasis associated with overt EMT was lowered and at the limit of significant threshold (*P*=0.0511). HPV status was not related with MFS and there was no interaction between HPV status and EMT (*P*=0.61).

Overt EMT was associated with higher risk of progression in univariate (*P*=0.0386, [Figure 2B](#fig2){ref-type="fig"}) and in multivariate analyses but was not related to the other outcomes.

Prognostic value of EMT combined with HPV status
------------------------------------------------

If we combined both EMT markers (vimentin expression and down-regulation of E-cadherin) with HPV status, there was a significant worse MFS when overt EMT expression was detected in HPV-negative OPC and when down-regulation of E-cadherin was present in both HPV-positive and -negative OPC, in multivariate analyses ([Table 3](#tbl3){ref-type="table"}).

Discussion
==========

The present prospective study on 296 patients confirms the numerous data of the literature reporting the detection of HPV infection as a good independent prognostic marker in OPC ([@bib7]; [@bib20]; [@bib15]; [@bib13]; [@bib40]). Indeed, HPV status is an independent prognostic factor for PFS. Thus, HPV detection represents a good approach to evaluate the outcome of OPC.

The role of EMT in the prognosis of HNSSC, especially OPC, has also been well studied using various different approaches: expression of transcriptional factors implicated in EMT such as Snail ([@bib46]; [@bib24]; [@bib31]), Slug ([@bib24]; [@bib44]; [@bib4]), Twist ([@bib24]; [@bib26]), SIP-1 ([@bib24]) and ZEB1 ([@bib18]), down-regulation of the E-cadherin/catenin complex ([@bib1]; [@bib17]; [@bib45]; [@bib26]; [@bib13]; [@bib33]; [@bib41]; [@bib4]) and expression of vimentin ([@bib13]; [@bib36]; [@bib41]) with different thresholds. Most of these studies reported a worse outcome associated with EMT with poor PFS ([@bib36]), disease free survival (DFS; [@bib31]; [@bib4]), [@bib18] and OS ([@bib26]; [@bib13]; [@bib33]; [@bib18]; [@bib36]). Nevertheless, considering the DFS, [@bib41] stated that EMT in OPC was not involved as a specific prognostic marker, but was only significantly associated with lymph node metastases. In our present work, the expression and particularly the loss of cell adhesion molecules E-cadherin and *β*-catenin, were not reliable markers for the OS of OPC, in agreement with the findings of [@bib1] using similar thresholds. These molecules were present on cancer cell membranes in a large majority of OPC whatever their stage and outcome. However, contrary to the data of [@bib1], in multivariate analysis, lower E-cadherin expression with a score \<12 had a higher risk of metastasis. These latter results confirm the recent data of [@bib13] and the meta-analysis of [@bib45] concluding that aberrant E-cadherin expression is a poor prognostic factor in HNSSC. In another way, vimentin expression in \>25% of cancer cells was a relevant hallmark of tumour aggressiveness, generally associated with poor differentiation in OPC. Indeed, in our study, we found that vimentin expression was an independent prognostic factor of PFS and at the limit of significance for MS. There was a 2.53-fold higher risk of metastasis when more than 25% of cancer cells expressed vimentin. Thus, in our experience, EMT evaluated by E-cadherin and vimentin expression, is a reliable prognostic marker of poor outcome in OPC.

The relationship between HPV infection indicating a good prognosis, and EMT classically associated with a more aggressive behaviour of tumour cells, is more complex. The role of HPV oncogenic proteins in the physiopathology of EMT has also been recently proposed. [@bib21] demonstrated that HPV16 E6 and E7 induce expression of transcriptional factors Slug, Twist, ZEB1 and ZEB2 involved in EMT. [@bib14] showed that expression of HPV16 E7 oncoprotein in normal epithelial cells caused increased levels of vimentin and fibronectin, whereas E-cadherin expression decreased. [@bib28] reported an epigenetic repression of E-cadherin by HPV16 E7. [@bib3] described the effects of HPV16 E5, E6 and E7 proteins impairing E-cadherin expression in trophoblastic cells. In another way, it has also been described a high propensity for EMT induced by EGF/TGF*β*1, in p16^INK4a^ positive OPC cells compared to p16^ink4a^ negative cells ([@bib40]) and a switch from FGFR2b to FGFR2c and EMT induced by HPV16 E5 ([@bib35]). *In vivo*, two recent papers with limited series of cases, 79 patients ([@bib13]) and 53 patients ([@bib41]) showed a paradoxical association of HPV infection and EMT in OPC. In both studies, HPV infection was assessed by DNA detection using PCR, associated with p16^INK4a^ detection ([@bib13]). The authors considered that EMT was only involved in the local lymph node metastatic process, frequently observed in HPV-related OPC ([@bib37]; [@bib19]). A third study on 42 cases, using HPV detection by *in situ* hybridisation, also provided evidence of Snail role as a molecular marker for regional metastasis in HNSSCs ([@bib31]). But Snail positivity appeared independent of HPV16 detection and p16^INK4a^ expression. Contrary to all these *in vivo* and *in vitro* data, in our cohort of 296 patients, there was a significant relation between p16^INK4a^ negative tumours and EMT. However, it has to be emphasised that 24 out 219 HPV negative carcinomas (10.9%) expressed p16^INK4a^. Indeed, p16^INK4a^ expression alone represents a less relevant proof of active HPV infection than the combined detection of DNA and E6/E7 mRNA. Using this latter approach, we did not find any significant relation between the absence of an active HPV infection and EMT (*P*=0.1139). This non significant association of EMT with HPV status may be explained by a mixed subpopulation with associated different risk factors (HPV, tobacco and alcohol) which may interfere in the tumorigenic pathways of these carcinomas. Indeed, 28 patients (36.6%) were smokers in our population of 77 HPV positive patients, and it has been well demonstrated that nicotine promotes EMT in HNSSC ([@bib42]). Thus, our results emphasise the necessity to take in account other factors than HPV status such as EMT, for the prognosis of OPC.

In conclusion, our study confirms the data of literature on the good prognosis of HPV infection in OPC and points out EMT as an unfavourable marker of evolution in all these carcinomas. Of particular interest is that these two factors act independently, and when combined, they bring significant additional information on MFS of OPC. In consequence, the detection of EMT in OPC represents another reliable approach in the prognosis and eventually the management of these cancers ([@bib10]) whatever their HPV status. These findings have particularly to be taken into account considering the different therapeutic protocols actually proposed for HPV positive OPC.

Research support
----------------

This study was funded by grants from the Programme Hospitalier de Recherche Clinique, French Ministry of Health (AOM 08104, AOM 11293).

The sponsor was Assistance Publique- Hôpitaux de Paris (Département de la Recherche Clinique et du Développement, Ile de France). We thank Mireille Toy Miou and France Guyot-Rousseau from the Clinical Research Unit of East of Paris (URC-Est), Saint Antoine University Hospital (Assistance Publique-Hôpitaux de Paris and Pierre-et-Marie Curie University---Paris 6) for study coordination and logistics, Judith Leblanc from the Clinical Research Center of East of Paris (CRC-Est), Saint Antoine University Hospital (Assistance Publique-Hôpitaux de Paris) for her logistic support and Silvia Franceschi for helpful discussion.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

The authors declare no conflict of interest.

![**Expression of p16^ink4a^ in tumour cells of OPC (**A**). Vimentin is expressed in tumour clusters at the invasion front (**B**) while E-cadherin (**C**) and *β*-catenin (**D**) are still present in tumour cell membranes in the same territory of an OPC (× 250).**](bjc2016434f1){#fig1}

![(**A**) Kaplan--Meier estimation of MFS according to EMT level. (**B**) Kaplan--Meier estimation of PFS according to EMT level. (**C**) Kaplan--Meier estimation of MFS according to E-Cadherin expression. The full colour version of this figure is available at *British Journal of Cancer* online.](bjc2016434f2){#fig2}

###### Baseline characteristics according to EMT markers

  **Characteristics**             **Vimentin**   **E-cadherin**   ***β*****-catenin**   **Nuclear** ***β*****-catenin**   **EMT**[a](#t1-fn2){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                    
  ------------------------------ -------------- ---------------- --------------------- --------------------------------- ------------------------------------ ---------------------------------------------- ---------------- --------------- -------------- ---------------------------------------------- ---------------- --------------- -------------- ---------------------------------------------- --------- --------- ---------------------------------------------- ---------- ---------- ----------- ----------------------------------------------
                                     **0%**        **0--10%**       **10**--**25%**             **25**--**50%**                       **\>50%**                ***P*****-value**[b](#t1-fn3){ref-type="fn"}   **12**--**16**   **8**--**12**   **0**--**8**   ***P*****-value**[b](#t1-fn3){ref-type="fn"}   **12**--**16**   **8**--**12**   **0**--**8**   ***P*****-value**[b](#t1-fn3){ref-type="fn"}   **Neg**   **Pos**   ***P*****-value**[b](#t1-fn3){ref-type="fn"}   **None**   **Mild**   **Overt**   ***P*****-value**[b](#t1-fn3){ref-type="fn"}
  **Age**                             62±9            59±9               59±10                       60±9                               59±11                        0.33[c](#t1-fn4){ref-type="fn"}              60±10            62±7           66±11             0.20[c](#t1-fn4){ref-type="fn"}              60±10            64±9            62±8             0.03[c](#t1-fn4){ref-type="fn"}           60±9      60±15          0.92[d](#t1-fn5){ref-type="fn"}            61±9      59±10       59±10           0.56[c](#t1-fn4){ref-type="fn"}
  **Gender**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Men                                  85              62                 31                          19                                  29                                       0.08                            203              20              3                             0.54                            193              24              9                             0.83                         217        9                          0.66                         147         31         48                           0.11
                                      70.3            76.5               91.2                        82.6                                78.4                                                                      75.8            83.3             75                                                            76.3             80             69.2                                                       76.1      81.8                                                      72.8       91.2        80                             
  Women                                36              19                  3                           4                                  8                                                                         65               4              1                                                              60               6              4                                                          68         2                                                        55         3          12                             
                                      29.8            23.5                8.8                        17.4                                21.6                                                                      24.3            16.7             25                                                            23.7             20             30.8                                                       23.9      18.2                                                      27.2       8.8         20                             
  Total                               121              81                 34                          23                                  37                                                                       268              24              4                                                             253              30              13                                                         285       11                                                       202         34         60                             
  **Tobacco smoking**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Never                                17              12                  2                           1                                  5                                        0.13                             34               2              1                             0.63                             1                3              33                            0.73                         33         4                          0.03                          29         2           6                           0.08
                                      14.1            14.8                5.9                         4.4                                13.5                                                                      12.7             8.3             25                                                            7.7              10              13                                                        11.6      36.4                                                      14.4       5.9         10                             
  Former ⩾10 years                     18              10                  5                           2                                  2                                                                         33               2              2                                                              2                5              30                                                         36         1                                                        28         5           4                             
                                      14.9            12.4               14.7                         8.7                                5.4                                                                       12.3             8.3             50                                                            15.4            16.7            11.9                                                       12.6       9.1                                                      13.9       14.7        6.7                            
  Former \<10 years or current         86              59                 27                          20                                  30                                                                       201              20              1                                                              10              22             190                                                         216        6                                                       145         27         50                             
                                      71.1            72.8               79.4                         87                                 81.1                                                                       75             83.3             25                                                            76.9            73.3            75.1                                                       75.8      54.6                                                      71.8       79.4       83.3                            
  Total                               121              81                 34                          23                                  37                                                                       268              24              4                                                              13              30             253                                                         285       11                                                       202         34         60                             
  **Alcohol drinking**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Never- or former ⩾10 years           39              25                  8                           6                                  8                                        0.15                             73              10              3                             0.01                             71              10              5                             0.33                         81         5                          0.22                          64         8          14                           0.17
                                      32.2            30.9               23.5                        26.1                                21.6                                                                      27.2            41.7             75                                                            28.1            33.3            38.5                                                       28.4      45.5                                                      31.7       23.5       23.3                            
  Former \<10 years or current         82              56                 26                          17                                  29                                                                       195              14              1                                                             182              20              8                                                          204        6                                                       138         26         46                             
                                      67.8            69.1               76.5                        73.9                                78.4                                                                      72.8            58.3             25                                                            71.9            66.7            61.5                                                       71.6      54.6                                                      68.3       76.5       76.7                            
  Total                               121              81                 34                          23                                  37                                                                       268              24              4                                                             253              30              13                                                         285       11                                                       202         34         60                             
  **Primary tumour site**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Tonsil                               59              52                 16                          10                                  21                                       0.82                            144              13              1                             0.49                            140              11              7                             0.25                         149        9                          0.05                         111         16         31                           0.55
                                      48.8            64.2               47.1                        43.5                                56.8                                                                      53.7            54.2             25                                                            55.3            36.7            53,9                                                       52.3      81.8                                                       55        47.1       51.7                            
  Other                                62              29                 18                          13                                  16                                                                       124              11              3                                                             113              19              6                                                          136        2                                                        91         18         29                             
                                      51.2            35.8               52.9                        56.5                                43.2                                                                      46.3            45.8             75                                                            44.7            63.3            46.2                                                       47.7      18.2                                                      45.1       52.9       48.3                            
  Total                               121              81                 34                          23                                  37                                                                       268              24              4                                                             253              30              13                                                         285       11                                                       202         34         60                             
  **UICC stage**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  1--2                                 20              9                   3                           2                                  1                                        0.31                             29               6              0                             0.02                             28               6              1                             0.02                         35         0                          0.24                          29         3           3                           0.42
                                      16.5            11.1                8.8                         8.7                                2.7                                                                       10.8             25              0                                                             11.1             20             7.7                                                        12.3        0                                                       14.4       8.8          5                             
  3                                    27              22                 13                           7                                  13                                                                        70              10              2                                                              63              11              8                                                          79         3                                                        49         13         20                             
                                      22.3            27.2               38.2                        30.4                                35.1                                                                      26.1            41.7             50                                                            24.9            36.7            61.5                                                       27.7      27.3                                                      24.3       38.2       33.3                            
  4                                    74              50                 18                          14                                  23                                                                       169               8              2                                                             162              13              4                                                          171        8                                                       124         18         37                             
                                      61.2            61.7               52.9                        60.9                                62.2                                                                      63.1            33.3             50                                                             64             43.3            30.8                                                        60       72.7                                                      61.4       52.9       61.7                            
  Total                               121              81                 34                          23                                  37                                                                       268              24              4                                                             253              30              13                                                         285       11                                                       202         34         60                             
  **HPV status**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Negative                             84              58                 28                          22                                  27                                       0.1                             198              19              2                             0.46                            183              26              10                            0.23                         213        6                          0.13                         142         28         49                          \<0.05
                                      69.4            71.6               82.4                        95.7                                 73                                                                       73.9            79.2             50                                                            72.3            86.7            76.9                                                       74.7      54.6                                                      70.3       82.4       81.7                            
  Positive                             37              23                  6                           1                                  10                                                                        70               5              2                                                              70               4              3                                                          72         5                                                        60         6          11                             
                                      30.6            28.4               17.7                         4.4                                 27                                                                       26.1            20.8             50                                                            27.7            13.3            23.1                                                       25.3      45.5                                                      29.7       17.7       18.3                            
  Total                               121              81                 34                          23                                  37                                                                       268              24              4                                                             253              30              13                                                         285       11                                                       202         34         60                             

Abbreviations: EMT=epithelial to mesenchymal transition; HPV=human papillomavirus; UICC=union for international cancer control.

EMT according to vimentin expression---none: 0--10%, mild: 11--25%, overt: \>25%.

*P*-value: Mantel--Haenzel *χ*^2^ test, except for age comparison.

Kruskall--Wallis test.

Wilcoxon test.

Data are mean±s.d. or *n* and %.

###### MFS and progression-free survival according to EMT markers

  **Variable**                          **MFS univariate analysis HR (95% CI)**[a](#t2-fn2){ref-type="fn"}   **MFS multivariate analysis HR (95% CI)**[b](#t2-fn3){ref-type="fn"}   **PFS univariate analysis HR (95% CI)**[a](#t2-fn2){ref-type="fn"}   **PFS multivariate analysis HR (95% CI)**[b](#t2-fn3){ref-type="fn"}
  ------------------------------------ -------------------------------------------------------------------- ---------------------------------------------------------------------- -------------------------------------------------------------------- ----------------------------------------------------------------------
  **Vimentin**                                                                                                                                                                                                                                          
  0                                                                     1                                                                     1                                                                     1                                                                     1
  (0--10%)                                                      0.56 (0.15; 2.14)                                                     0.66 (0.16; 2.67)                                                     1.43 (0.92; 2.22)                                                     0.66 (0.16; 2.67)
  (10--25%)                                                     1.77 (0.46; 6.87)                                                     1.96 (0.43; 9.00)                                                     1.50 (0.83; 2.73)                                                     1.96 (0.43; 9.00)
  (25--50%)                                                     2.86 (0.80; 10.23)                                                    3.40 (0.84; 13.81)                                                    3.19 (1.75; 5.80)                                                     3.40 (0.84; 13.81)
  \>50%                                                         2.43 (0.81; 7.31)                                                     2.10 (0.63; 7.01)                                                     1.31 (0.74; 2.29)                                                     2.10 (0.63; 7.01)
  **E-cadherin**                                                                                                                                                                                                                                        
  (12--16)                                                              1                                                                     1                                                                     1                                                                     1
  (0--12)                                                       3.72 (1.35; 0.26)                                                     6.86 (1.98; 23.84)                                                    1.08 (0.60; 1.97)                                                     1.31 (0.70; 2.46)
  ***β***-catenin                                                                                                                                                                                                                                       
  (12--16)                                                              1                                                                     1                                                                     1                                                                     1
  (0--12)                                                       0.73 (0.21; 2.56)                                                     1.16 (0.31; 4.35)                                                     1.26 (0.77; 2.06)                                                     1.58 (0.93; 2.67)
  Nuclear ***β***-catenin                                                                                                                                                                                                                               
  Negative                                                              1                                                                     1                                                                     1                                                                     1
  Positive                                                      2.42 (0.50; 11.64)                                                    1.56 (0.29; 8.43)                                                     1.23 (0.48; 3.12)                                                     1.93 (0.74; 5.09)
  **EMT[c](#t2-fn4){ref-type="fn"}**                                                                                                                                                                                                                    
  None or mild                                                          1                                                                     --                                                                    1                                                                     1
  Overt                                                         2.77 (1.20; 6.39)                                                     2.53 (1.00; 6.41)                                                     1.52 (1.02; 2.26)                                                     1.57 (1.04; 2.37)

Abbreviations: CI=confidence interval; EMT=epithelial to mesenchymal transition; HPV=human papillomavirus; HR=hazard ratio; MFS=metastasis-free survival; PFS=progression-free survival; UICC=union for international cancer control.

Univariate HR stratified on hospital.

Multivariate HR, stratified on hospital and adjusted on age, gender, performance status, UICC stage, primary tumour sites, HPV status, smoking status, alcohol consumption and primary treatment.

EMT according to vimentin expression---none: 0--10%, mild: 11--25%, overt: \>25%.

###### MFS according to EMT markers combined with HPV status

  **Combination**                                   **MFS univariate analysis HR (95% CI)**[a](#t3-fn2){ref-type="fn"}   **MFS multivariate analysis HR (95% CI)**[b](#t3-fn3){ref-type="fn"}
  ------------------------------------------------ -------------------------------------------------------------------- ----------------------------------------------------------------------
  **EMT**[c](#t3-fn4){ref-type="fn"} **and HPV**                                                                        
  Without or mild EMT---HPV neg                                                     1                                                                     1
  Without or mild EMT---HPV pos                                             1.31 (0.46; 3.73)                                                     3.10 (0.90; 10.65)
  Overt EMT---HPV negative                                                  3.21 (1.19; 8.62)                                                     3.15 (1.08; 9.20)
  Overt EMT---HPV positive                                                  2.56 (0.53; 12.36)                                                    4.07 (0.64; 25.89)
  **E-cadherin and HPV**                                                                                                
  E-cadherin (12--16)---HPV neg                                                     1                                                                     1
  E-cadherin (12--16)---HPV pos                                             0.97 (0.36; 2.59)                                                     2.05 (0.69; 6.14)
  E-cadherin (0--12)---HPV neg                                              3.15 (0.93; 10.66)                                                    6.99 (1.49; 32.81)
  E-cadherin (0--12)---HPV pos                                              5.49 (1.07; 28.09)                                                   13.61 (1.46; 126.7)

Abbreviations: CI=confidence interval; EMT=epithelial to mesenchymal transition; HPV=human papillomavirus; HR=hazard ratio; MFS=metastasis-free survival; UICC=union for international cancer control.

Univariate HR, stratified on hospital.

Multivariate HR, stratified on hospital and adjusted on age, gender, performance status, UICC stage, primary tumour sites, smoking status, alcohol consumption and primary treatment.

EMT according to vimentin expression---none: 0--10%, mild: 11--25%, overt: \>25%.
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